Drug
Rasburicase clinical trials
Also written NK-631.
- studies test it
- 20
- open now
- 1
- in phase 3
- 4
- first study started
- 2002
Keep track of what changes. Save the rasburicase studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
20 studies that test it; most in 2003 (3)
| Year | Studies |
|---|---|
| 2002 | 1 |
| 2003 | 3 |
| 2004 | 3 |
| 2005 | 1 |
| 2006 | 3 |
| 2007 | 1 |
| 2008 | 3 |
| 2010 | 1 |
| 2011 | 2 |
| 2018 | 1 |
| 2022 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 2
- Phase 2
- 10
- Phase 3
- 4
- Phase 4
- 4
- No phase
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 8 · Other 12
Sanofi (8) · M.D. Anderson Cancer Center (3) · St. Jude Children's Research Hospital (1) · Goethe University (1) · Erasme University Hospital (1) · Washington University School of Medicine (1) · Massachusetts General Hospital (1) · Children's Oncology Group (1)
Often tested with
Tested in the same studies.
Allopurinol (4) · COPAD Regimen (1) · Febuxostat (1)
Studies
Open first, then newest update. How each study uses rasburicase is read from its arms, and is right about nine times in ten.
Testing it · 20
- Rasburicase Treatment in Chronic Gouty ArthritisRecruitingPhase 4Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNCT05312268Written as Rasburicase
- Mature B-Cell Lymphoma And Leukemia Study IIIActive, not recruitingPhase 2/3St. Jude Children's Research HospitalNCT01046825Written as COP, COPD M3, CYM
- Treatment of Hyperuricemia With Rasburicase in Patients With Acute Lymphoblastic Leukemia or High Grade LymphomaCompletedPhase 3Goethe UniversityNCT00199043Written as Rasburicase
- Uric Acid Effects on Endothelium and Oxydative StressCompletedNot applicableErasme University HospitalNCT03395977Written as Rasburicase
- Rasburicase in Patients at High Risk for Tumor Lysis Syndrome (TLS) During Cycle-2CompletedPhase 2M.D. Anderson Cancer CenterNCT01200485Written as Rasburicase
- Effect of Reducing Uric Acid on Insulin Sensitivity and Oxidative StatusCompletedNot applicableWashington University School of MedicineNCT01931527Written as Rasburicase
- Rasburicase and Allopurinol in Treating Patients With Hematologic MalignanciesTerminatedPhase 2Roswell Park Cancer InstituteNCT01564277Written as rasburicase
- Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell TransplantCompletedPhase 1Massachusetts General HospitalNCT00513474Written as rasburicase
- Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or LymphomaCompletedPhase 2Children's Oncology GroupNCT00057811Written as rasburicase
- Rasburicase (Fasturtec) Registration TrialTerminatedPhase 3SanofiNCT00607152Written as Rasburicase
- Rasburicase in Patients at Risk for Tumor Lysis SyndromeCompletedPhase 2M.D. Anderson Cancer CenterNCT00628628Written as As Needed Rasburicase
- Lowering Serum Uric Acid to Prevent Acute Kidney InjuryCompletedPhase 2University of FloridaNCT00756964Written as Rasburicase
- Pharmacokinetic Evaluation of Rasburicase in Patients With Leukemia and/or Lymphoma at High Risk of TLSCompletedPhase 1/2M.D. Anderson Cancer CenterNCT00360438Written as Rasburicase
- Rasburicase for the Treatment/Prevention of Hyperuricemia in Adult Patients With Relapsing Aggressive Non Hodgkin's LymphomaTerminatedPhase 2SanofiNCT00664144Written as Rasburicase (SR29142)
- Rasburicase Versus Allopurinol in Tumor Patients at Risk for Hyperuricemia and Tumor Lysis SyndromeCompletedPhase 3SanofiNCT00230178Written as Rasburicase (SR29142)
- Rasburicase as a Uricolytic Therapy for Hyperuricemia in Patients With Leukemia or LymphomaCompletedPhase 2SanofiNCT00631579Written as Rasburicase (SR29142)
- Rasburicase in Tumor Lysis SyndromeCompletedPhase 4SanofiNCT00302653Written as Rasburicase
- Rasburicase for HyperuricemiaCompletedPhase 2SanofiNCT00290992Written as rasburicase (SR29142)
- Study of Rasburicase as Treatment or Prevention of Hyperuricemia Associated With Tumor Lysis Syndrome in Patients With Relapsed or Refractory Lymphoma, Leukemia, or Solid Tumor MalignancyCompletedPhase 4SanofiNCT00230217Written as Rasburicase (SR29142)
- Rasburicase for Treatment of Hyperuricemia in Children and Adolescence Patients With Tumor Lysis SyndromeCompletedPhase 4SanofiNCT00563771Written as Rasburicase
Given in every arm · 1 — rasburicase is usual care beside what is tested
Codes
What other systems call rasburicase · ClinicalTrials.gg INT004493
- MeSH (NLM) C469709rasburicaseOne source ClinicalTrials.gov
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C469709 | rasburicase | One source ClinicalTrials.gov |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.